Latest news and press releases about NovaBridge Biosciences (NBP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors.
Price
| Price | $1.57 |
| Market Cap | $181M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.95 |
| EV / EBITDA | -0.36 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -1.45% |
| Return on Invested Capital | -29.03% |
| Return on Assets | -21.17% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · ANNX · AURA · DMAC · DRTS · DSGN · ENGN
Explore sector: Healthcare · Biotechnology
More sections of NBP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks